Parekh Jai, Sharma Vikram, Robl Jared, Kshetri Rupesh, Osnard Michael, Vutthikraivit Wasawat, Arustamyan Michael, Deshmukh Abhishek, Rossen James, Horwitz Phillip A, Panaich Sidakpal
Department of Internal Medicine/Cardiovascular Disease, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Department of Internal Medicine/Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.
J Soc Cardiovasc Angiogr Interv. 2024 Feb 15;3(4):101310. doi: 10.1016/j.jscai.2024.101310. eCollection 2024 Apr.
Injury to the cardiac conduction system requiring a permanent pacemaker (PPM) implantation is a known adverse outcome of transcatheter aortic valve replacement (TAVR). Temporary-permanent pacemakers (TPPM) have been used as a bridge to PPM implantation in patients with systemic infection; however, there are only a few reports of its routine use in patients undergoing TAVR. This study aimed to assess the utility of routine use of TPPM in patients undergoing TAVR with a high risk of needing a PPM or those who develop high-grade conduction abnormalities during/after TAVR.
Between April 2015 and December 2021, 978 patients underwent TAVR at our institution, of whom 111 patients had TPPM placed before or during/after TAVR during the study period. In total, 89 patients were included in the final analysis.
The median age was 78 years (IQR, 71-84 years); 52 (58.4%) patients with preexisting native conduction disease were considered high risk for advanced heart block and had TPPM placed before TAVR. In addition, 37 (41.6%) patients had TPPM placed during/after TAVR. Of the 89 patients who received TPPM, 51 (57.3%) were treated with a balloon-expandable valve and 38 (42.7%) with a self-expandable valve. Of the patients who underwent TPPM placement, only 49 (55.1%) required a PPM, and TPPM was removed in 40 (44.9%) patients. TPPM was in place for a median of 6 days (IQR, 2-11 days). Only 1 of the 89 patients (1.1%) who received a TPPM had lead dislodgment. No other complications were noted. Median length of stay was 3 days (IQR, 2-4 days).
In patients with high-risk baseline conduction abnormalities before TAVR and those who develop new high-grade conduction abnormalities during/after TAVR, TPPM provides a feasible and safe method for pacing that could allow early ambulation, facilitate early discharge, and prevent unnecessary PPM implantations in some patients.
需要植入永久性起搏器(PPM)的心脏传导系统损伤是经导管主动脉瓣置换术(TAVR)已知的不良后果。临时-永久性起搏器(TPPM)已被用作全身感染患者植入PPM的过渡手段;然而,关于其在接受TAVR的患者中常规使用的报道很少。本研究旨在评估TPPM在接受TAVR且有高风险需要PPM或在TAVR期间/之后出现高度传导异常的患者中常规使用的效用。
2015年4月至2021年12月期间,978例患者在我院接受了TAVR,其中111例患者在研究期间于TAVR之前或期间/之后植入了TPPM。最终分析共纳入89例患者。
中位年龄为78岁(四分位间距,71 - 84岁);52例(58.4%)患有先天性传导疾病的患者被认为发生高级别心脏传导阻滞的风险较高,并在TAVR之前植入了TPPM。此外,37例(41.6%)患者在TAVR期间/之后植入了TPPM。在接受TPPM的89例患者中,51例(57.3%)接受了球囊扩张瓣膜治疗,38例(42.7%)接受了自膨胀瓣膜治疗。在接受TPPM植入的患者中,只有49例(55.1%)需要PPM,40例(44.9%)患者的TPPM被移除。TPPM在位的中位时间为6天(四分位间距,2 - 11天)。在接受TPPM的89例患者中,只有1例(1.1%)发生导线移位。未观察到其他并发症。中位住院时间为3天(四分位间距,2 - 4天)。
对于TAVR前基线传导异常高危以及在TAVR期间/之后出现新的高度传导异常的患者,TPPM提供了一种可行且安全的起搏方法,可允许早期活动,促进早期出院,并在一些患者中防止不必要的PPM植入。